TMCnet News

Altor BioScience Announces Upcoming Data Presentation on Efficacy and Safety of ALT-801 for Advanced Bladder Cancer at 2015 ASCO Annual Meeting
[May 28, 2015]

Altor BioScience Announces Upcoming Data Presentation on Efficacy and Safety of ALT-801 for Advanced Bladder Cancer at 2015 ASCO Annual Meeting


Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapies, announced today that it will present updated safety and efficacy data from its ongoing Phase 1b/2 study of ALT-801 in combination with gemcitabine and cisplatin in patients with advanced or metastatic chemo-refractory urothelial cancer. The data will be presented in Poster Discussion Session at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 29-June 2 in Chicago.

ALT-801 is a novel proprietary immunotherapy composed of IL-2 genetically fused to a soluble T-cell receptor (TCR) directed against a p53-derived tumor associated antigen. Altor's approach uses the TCR to guide IL-2 bioactivity to the tumor site, where the cytokine-stimulated immune system attacks the cancerous cells. ALT-801 exhibits a favorable pharmacokinetic and biodistribution profile, improved efficacy and lower toxicity compared to standard IL-2 treatment in various tumor efficacy models. In early phase clinical testing in patients with metastatic malignancies, ALT-801 was well tolerated in the out-patient setting at dose levels that provided treatment-induced immune responses and clinical benefit to patents. Altor has concluded two Phase 1/2 clinical studies of ALT-801 in combination with gemcitabine and cisplatin or gemcitabine alone in patients with advanced/metastatic urothelial cancer (ClinicalTrials.gov Identifier: NCT01326871). Altor is also conducting a clinical trial of ALT-801 in combination with gemcitabine in patients with Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasve bladder cancer (NMIBC) (ClinicalTrials.gov Identifier: NCT01625260).



Hing C. Wong, Ph.D., Chief Executive Officer and Chief Clinical Officer of Altor, stated, "We are very pleased to have the opportunity to present the clinical data on ALT-801 at ASCO 2015. In the current study, two independent groups of patients with metastatic chemo-refractory urothelial cancer showed high objective response rates, including complete responses, and prolonged median overall survival suggesting that ALT-801 plus gemcitabine/cisplatin therapy exhibits clinical activity. Results from correlative studies also suggest that treatment-dependent activation of the immune system plays a role in these responses. These findings could facilitate further evaluation of ALT-801 in combination with other immunotherapies, including checkpoint blockade, in this patient population, an approach we are actively pursuing."

Abstracts summarizing the results of the clinical studies in advanced/metastatic urothelial cancer (abstract #4515) and BCG-resistant NMIBC (abstract #e15509) are available at abstracts.asco.org. Additional data of ALT-801 plus gemcitabine and cisplatin for metastatic chemo-refractory urothelial cancer will be highlighted at the following ASCO 2015 Poster Discussion Session.


Abstract Title: Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (abstract #4515, poster board #185).

Presenter: Mayer N. Fishman, MD, PhD, Senior Member, Moffitt Cancer Center

Session Title: Poster Discussion Session - Genitourinary (Nonprostate) Cancer

Session Date, Time, Location:

General Poster Session - 6/01/15, 1:15-4:45 p.m. CT; McCormick Place: S Hall A

Poster Discussion Session - 6/01/15, 4:45-6:00 p.m. CT; McCormick Place: E Arie Crown Theater

The presenter and Altor attendees will be available following the discussion for networking.

About Altor BioScience

Altor is a privately held biotechnology company developing immunotherapies for treating cancer, viral infections, and inflammatory diseases based on its proprietary soluble T-cell receptor, Interleukin-15 superagonist and Tissue Factor antagonist platform technologies. Altor currently has five Phase 1 and two Phase 2 trials underway for its immunotherapeutics against cancer.

Visit www.altorbioscience.com for details.


[ Back To TMCnet.com's Homepage ]